The Life Sciences Report
Notable Quotes
"THLD's Phase 3 soft tissue sarcoma trial is likely to play out with topline results by Q3/15 or Q4/15." (1/27/15) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico More >
"CANF's oral psoriasis candidate has shown some very, very promising data." (1/27/15) Can-Fite BioPharma Ltd. - The Life Sciences Report Interview with Reni Benjamin More >
"There is opportunity for the FDA to accept a new drug application filing from SNSS." (1/27/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with Mara Goldstein More >
"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke More >
"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk Low: | ||
Celgene Corp.TICKER: CELG:NASDAQ
|
A summary of Expert Comments about Celgene Corp. is currently unavailable. You can find Expert Comments on companies similar to Celgene Corp. by clicking on the links below.